Luck, this is a nice find that provides insight about Neuromed's genesis.
We have lots of potential on the table with Dr. Snutch, but what will actually materialize is difficult to determine.
The interesting basic research findings must find their way through phase-3 without disqualifying side effects. This is a tall order and will require a multi-billion dollar partner like Merck. I hope they are back on board for good this time.